Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Illumina (ILMN) , which belongs to the Zacks Medical - Biomedical and Genetics industry.When looking at the last two reports, this genetic testing tools company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 115.52%, on average, in the last two quarters.For the last reported quarter, Illumina came out with e ...

Illumina, Inc. (ILMN) has announced a collaboration with NVIDIA (NVDA) to advance technology platforms for analyzing and interpreting multiomic data. By combining advancements in artificial intelligence (AI) with multiomic data at scale, the partnership seeks to optimize the analysis of vast amounts of data involved in multiomic research.The latest development aims to accelerate progress in clinical research, genomics AI development and drug discovery.ILMN Stock’s Trend in Response to the NewsFollowing the ...

Illumina, Inc. (NASDAQ:ILMN) 43rd Annual JPMorgan Healthcare Conference Call January 14, 2025 12:00 PM ET Company Participants Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Rachel Vatnsdal Perfect. Good morning, everyone. This is Rachel Vatnsdal from the Life Science Tools and Diagnostics team at JPMorgan. I'm joined today by Jacob from the Illumina team. So as a reminder, this is a 40 minute session. The first half wi ...

Key Points Company and Industry Overview - **Company**: Illumina, Inc. (NASDAQ: ILMN) - **Industry**: Life Science Tools and Diagnostics - **Event**: 43rd Annual JPMorgan Healthcare Conference Call - **Date**: January 14, 2025 - **Time**: 12:00 PM ET - **Participants**: Jacob Thaysen (CEO), Ankur Dhingra (CFO), Rachel Vatnsdal (JPMorgan) - **Duration**: 40 minutes (20 minutes presentation, 20 minutes Q&A) - **Focus**: Business overview, financial results, strategic direction, and future outlook Core Points and Arguments - **Business Growth**: Illumina has been pioneering next-generation sequencing (NGS) technology for over 25 years, making it a foundational tool in genomic research and clinical applications worldwide. - **Global Strength**: Illumina is operating from a position of global strength, with significant market presence and influence. - **2024 Results**: Preliminary Q4 and full year 2024 results will be covered, along with outlook for 2025. - **New Strategy**: Illumina is shifting its focus from cost per gigabase to providing the highest quality insights at the lowest end-to-end cost. - **Excitement for Future**: The company is incredibly excited about the path ahead and the opportunities it presents. Other Important Points - **Forward-Looking Statements**: The presentation includes forward-looking statements and non-GAAP measures, which are detailed in Illumina's SEC filing. - **Presentation Structure**: The presentation will cover four main areas: business overview, financial results, strategic direction, and future outlook. - **Q&A Session**: Approximately 20 minutes of the session will be dedicated to answering questions from participants.

Revenue Performance - Q4 2024 revenue of approximately $1.10 billion, up 1% from Q4 2023[4] - Full-year 2024 revenue of approximately $4.33 billion, down 2% from 2023[4] - Fiscal year 2025 guidance: constant currency revenue growth in the low single digits, with reported revenue expected between $4.28 billion and $4.4 billion[4] Operating Margin - GAAP operating margin of 16.7% for Q4 2024 and 34.2% for full-year 2024[4] - Non-GAAP operating margin of 19.7% for Q4 2024 and 21.3% for full-year 2024[4] - Non-GAAP operating margin expected to be approximately 23% for fiscal year 2025[4] Earnings Per Share (EPS) - GAAP diluted EPS of $0.77 - $0.79 for Q4 2024 and $5.65 - $5.67 for full-year 2024[4] - Non-GAAP diluted EPS of $0.91 - $0.93 for Q4 2024 and $4.12 - $4.14 for full-year 2024[4] - Non-GAAP diluted EPS growth expected to be approximately 10% for fiscal year 2025[4] Cash Flow - Free cash flow of approximately $1.07 billion for 2024[4]

SAN DIEGO, Jan. 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2024 and preliminary outlook for fiscal year 2025 ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time). The webcast can be accessed through Illumina's website at investor.illumina.com. Core Illumina Revenue of approxi ...

Partnership Overview - Illumina and NVIDIA are collaborating to combine AI advancements with multiomic data at scale, leveraging Illumina's sequencing technology and NVIDIA's AI tools to accelerate drug discovery and clinical development [1][8] - The partnership aims to integrate NVIDIA's RAPIDS™ accelerated data science software, BioNeMo™ platform, and MONAI for spatial cell imaging workflows with Illumina's Connected Analytics platform [2] - The collaboration will enable DRAGEN algorithms on NVIDIA GPUs and incorporate NVIDIA's image processing and single-cell tertiary analysis tools into Illumina's multiomics module [3] Technological Integration - Illumina's DRAGEN-powered multiomics offerings, genomics AI tools, and Connected Analytics platform have streamlined genomic data generation and analysis [10] - NVIDIA's AI and data science tools will be integrated with Illumina's sequencing and analytics platforms to drive the next generation of genomics interpretation [3] - Customers will be able to leverage NVIDIA's biology foundation models with their proprietary datasets for tasks such as cell state or gene transcription prediction [5] Industry Impact - The collaboration aims to democratize genomics for drug discovery through AI-powered insights, enabling deeper biological insights and total workflow solutions for customers [3] - The partnership is expected to advance technology platforms for the analysis and interpretation of multiomic data, accelerating progress in clinical research and genomics AI development [8] - Illumina's investment in AI for genomic interpretation includes leading algorithms such as SpliceAI, PrimateAI-3D, and Emedgene xAI [10]

Study will generate a key reference data set with Illumina Protein Prep solution SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson & Johnson, and Novartis. The pilot program is based on Illumina's upcoming proteomics assay, Illumina Protein Prep™, powered by SOMAmer® ...

SAN DIEGO, Jan. 9, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2024 following the close of market on Thursday, February 6, 2025. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call D ...

Illumina, Inc. (ILMN) has announced a series of updates to its NovaSeq X Series. The company’s single-flow-cell NovaSeq X Sequencing System is now available for the first time, alongside the software v1.3 upgrade to elevate sequencing performance and advance data quality.In addition, the new NovaSeq X 25B 100 and 200-cycle kits are now available under Illumina's brand following the company's acquisition of Fluent.ILMN Stock’s Likely Trend Following the NewsAfter yesterday’s announcement, Illumina shares edg ...